Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABCELLERA BIOLOGICS INC.

(ABCL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbCellera Biologics : , Lilly Announce Expanded FDA Emergency Use Authorization for COVID-19 Antibody Therapy -- Shares Jump in Pre-Market

09/17/2021 | 06:02am EDT


© MT Newswires 2021
All news about ABCELLERA BIOLOGICS INC.
10/14ABCELLERA BIOLOGICS : to Report Third Quarter 2021 Financial Results on November 9, 2021
BU
10/12Salipro Biotech AB Enters into A Collaboration and License Agreement with Abcellera for..
CI
09/23Health Care Stocks Slightly Higher in Premarket Thursday
MT
09/23EVEREST MEDICINES : Strikes R&D Tie-Up with Nasdaq-listed AbCellera Biologics for Therapeu..
MT
09/23ABCELLERA BIOLOGICS : Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivi..
PU
09/23ABCELLERA BIOLOGICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/23ABCELLERA BIOLOGICS : Everest Medicines Enter Multi-Year Collaboration, License Agreement
MT
09/22ABCELLERA BIOLOGICS : and Everest Medicines Announce Multi-Target Collaboration to Advance..
BU
09/22Abcellera Biologics Inc. and Everest Medicines Limited Announces Multi-Target Collabora..
CI
09/21ABCELLERA BIOLOGICS : Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivi..
PU
More news
Analyst Recommendations on ABCELLERA BIOLOGICS INC.
More recommendations
Financials (USD)
Sales 2021 264 M - -
Net income 2021 96,3 M - -
Net cash 2021 680 M - -
P/E ratio 2021 47,2x
Yield 2021 -
Capitalization 4 342 M 4 342 M -
EV / Sales 2021 13,8x
EV / Sales 2022 36,2x
Nbr of Employees 302
Free-Float 68,5%
Chart ABCELLERA BIOLOGICS INC.
Duration : Period :
AbCellera Biologics Inc. Technical Analysis Chart | ABCL | CA00288U1066 | MarketScreener
Technical analysis trends ABCELLERA BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 15,58 $
Average target price 45,40 $
Spread / Average Target 191%
EPS Revisions
Managers and Directors
Carl Lars G. Hansen President, Chief Executive Officer & Director
Andrew Booth Chief Financial Officer
Marcie Thiessen Finance Director
Ester Falconer Chief Technology Officer
Véronique Lecault Chief Operating Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
ABCELLERA BIOLOGICS INC.-59.07%4 590
MODERNA, INC.230.95%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.42.93%49 145
SEAGEN INC.1.46%31 933
CELLTRION, INC.-38.02%25 328